Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

Group 1 - Arcutis Biotherapeutics, Inc. is scheduled to report its third quarter 2024 financial results on November 6, 2024, after U.S. financial markets close, followed by a conference call and webcast at 4:30 p.m. ET [1] - The company will also participate in the Guggenheim Securities Healthcare Innovation Conference on November 11, 2024, with a fireside chat scheduled for 3:30 p.m. ET [2] - Arcutis is a commercial-stage biopharmaceutical company focused on immuno-dermatology, with a portfolio that includes three FDA-approved products and a robust pipeline targeting various inflammatory dermatological conditions [3] Group 2 - The company emphasizes its commitment to addressing the urgent needs of individuals with immune-mediated dermatological diseases through meaningful innovations [3] - Arcutis' dermatology development platform is designed to build differentiated therapies against biologically validated targets, showcasing its expertise in the field [3]